CARVEDILOL PHOSPHATE Drug Patent Profile

When do Carvedilol Phosphate patents expire, and when can generic versions of Carvedilol Phosphate launch?

Carvedilol Phosphate is a drug marketed by Impax Labs Inc and Sun Pharm Industries and is included in two NDAs.

The generic ingredient in CARVEDILOL PHOSPHATE is carvedilol phosphate. There are thirty-seven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Carvedilol Phosphate

A generic version of CARVEDILOL PHOSPHATE was approved as carvedilol phosphate by SUN PHARM INDUSTRIES on October 25^th, 2017.

Summary for CARVEDILOL PHOSPHATE

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	5
Patent Applications:	53
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CARVEDILOL PHOSPHATE
What excipients (inactive ingredients) are in CARVEDILOL PHOSPHATE?	CARVEDILOL PHOSPHATE excipients list
DailyMed Link:	CARVEDILOL PHOSPHATE at DailyMed

Recent Clinical Trials for CARVEDILOL PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1
GlaxoSmithKline	Phase 1/Phase 2
University of Minnesota - Clinical and Translational Science Institute	Phase 1/Phase 2

See all CARVEDILOL PHOSPHATE clinical trials

Pharmacology for CARVEDILOL PHOSPHATE

Drug Class	alpha-Adrenergic Blocker beta-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists Adrenergic beta1-Antagonists Adrenergic beta2-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for CARVEDILOL PHOSPHATE

C07AG	Alpha and beta blocking agents
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for CARVEDILOL PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COREG CR	Extended-release Capsules	carvedilol phosphate	10 mg and 20 mg	022012	1	2008-03-18
COREG CR	Extended-release Capsules	carvedilol phosphate	40 mg	022012	1	2007-12-21
COREG CR	Extended-release Capsules	carvedilol phosphate	80 mg	022012	1	2007-11-19

US Patents and Regulatory Information for CARVEDILOL PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax Labs Inc	CARVEDILOL PHOSPHATE	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	204717-001	May 7, 2018	AB	RX	No	No
Sun Pharm Industries	CARVEDILOL PHOSPHATE	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	090132-003	Oct 25, 2017	AB	RX	No	Yes
Impax Labs Inc	CARVEDILOL PHOSPHATE	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	204717-004	May 7, 2018	AB	RX	No	No
Sun Pharm Industries	CARVEDILOL PHOSPHATE	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	090132-004	Oct 25, 2017	AB	RX	No	No
Impax Labs Inc	CARVEDILOL PHOSPHATE	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	204717-002	May 7, 2018	AB	RX	No	No
Impax Labs Inc	CARVEDILOL PHOSPHATE	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	204717-003	May 7, 2018	AB	RX	No	No
Sun Pharm Industries	CARVEDILOL PHOSPHATE	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	090132-002	Oct 25, 2017	AB	RX	No	No

Market Dynamics and Financial Trajectory for Carvedilol Phosphate

Last updated: March 5, 2026

Carvedilol phosphate is an extended-release formulation of carvedilol, a non-selective beta-blocker with alpha-1 blocking activity, primarily used in managing hypertension and heart failure. This analysis outlines its current market landscape, growth drivers, challenges, and financial projections.

Market Overview

Carvedilol phosphate entered the market in the early 2000s following the approval of Coreg CR (carvedilol phosphate) by the FDA in 2007. It is marketed under brand names such as Coreg CR by Roche. Its indication spectrum extends to treatment of hypertension, NYHA Class II-IV heart failure, and post-myocardial infarction management.

The global beta-blocker market was valued at approximately USD 4.2 billion in 2022, with carvedilol accounting for about 20-25% of this segment. The extended-release formulations like carvedilol phosphate account for 40-50% of carvedilol sales globally, driven by improved compliance and dosage control.

Market Drivers

Increasing Prevalence of Cardiovascular Diseases

• Hypertension affects over 1.3 billion people worldwide.
• Heart failure prevalence is projected to increase segmentally at a CAGR of 2.5% through 2030 (WHO, 2021).
• Rising incidence fuels demand for long-term management drugs like carvedilol phosphate.

Advancements in Formulation Technologies

• Extended-release formulations improve adherence in chronic conditions.
• Carvedilol phosphate offers once-daily dosing, enhancing patient compliance over immediate-release versions.

Aging Population

• Global demographic shifts lead to higher cardiovascular disease treatment needs.
• Patients aged 60+ are primary candidates, expanding market potential.

Strategic Approvals and Expansion

• Regulatory approvals for new indications or formulations bolster sales.
• Cardinal markets such as the U.S., EU, and Japan see consistent demand.

Market Challenges

Patent and Competitive Landscape

• Patent exclusivity for Coreg CR expired in 2016 in the U.S.
• Generics dominate the market, leading to price erosion.
• Several non-branded competitors reduce profit margins.

Pricing and Reimbursement Pressures

• Governments and insurers seek price reductions in chronic therapies.
• Cost containment impacts revenue growth, especially in public healthcare systems.

Manufacturing Complexity

• Extended-release formulations require sophisticated technology.
• High production costs may deter new entrants.

Financial Trajectory

Revenue Trends

• Estimated global sales of carvedilol phosphate formulations approached USD 1 billion in 2022.
• The U.S. market accounts for roughly 60% of revenue, given high prevalence of cardiovascular diseases and health insurance coverage.
• Post-patent expiration, sales decline were observed, with a 15% decrease in North America from 2016-2020.

Future Projections (2023-2028)

• Market growth rate projected at a CAGR of 3-4%, driven by new formulations and expanding patient base.
• Market expansion anticipated in APAC and LATAM due to improving healthcare infrastructure.
• Revenue for branded carvedilol phosphate expected to stabilize around USD 700 million annually by 2028, considering increasing generic penetration.

Investment Trends

• Pharma companies invest in developing long-acting beta-blockers with improved side effect profiles.
• Mergers and acquisitions aim to acquire generic rights or expand product portfolios.

Discounted Revenue and Pricing Outlook

Year	Estimated Revenue (USD billion)	Key Factors
2023	0.95 - 1.05	Market stabilization, generic competition.
2025	1.0 - 1.1	Adoption of new formulations, increasing demand.
2028	0.7 - 0.8	Market maturity, higher generic share.

Competitive Landscape

Key players include:

• Roche (Coreg CR): Original patent holder, now facing generic competition.
• Mylan (now part of Viatris): Produces generic carvedilol phosphate.
• Teva Pharmaceuticals: Offers branded and generic versions.
• Sun Pharmaceutical: Market share in emerging markets.

Market share distribution favors generics, which hold 70-80% of sales in mature markets.

Regulatory Environment

• FDA approved carvedilol phosphate in 2007.
• Patent expiration in the U.S. and EU created a shift toward generic products.
• Some markets enforce pricing controls affecting revenue.

Strategic Implications

• Innovator companies focus on reformulations or combination therapies.
• Generic manufacturers leverage cost advantages to expand market share.
• Market opportunities exist in emerging economies with growing cardiovascular disease burdens.

Key Takeaways

• Carvedilol phosphate sustains steady demand in cardiovascular disease management.
• Patent expiry diluted profitability in mature markets but spurred growth via generics.
• The global market is expected to grow modestly, mainly through geographic expansion.
• Price competition pressures profits but is countered by demand for long-acting formulations.
• Future growth hinges on innovation, market penetration in developing countries, and regulatory repositioning.

FAQs

What factors influence carvedilol phosphate's market share?
Patent status, generic competition, formulation improvements, and regional regulations primarily determine market share.

How do patent expirations affect revenue?
Patent expirations lead to generic entry, reducing prices and profits for branded formulations, impacting overall revenue.

Are there upcoming innovations in carvedilol phosphate formulations?
Research focuses on combination therapies and new delivery systems, but no major advancements have gained regulatory approval yet.

Which regions show the highest growth potential?
Emerging markets in Asia-Pacific and Latin America exhibit strong growth potential due to increasing cardiovascular disease prevalence and expanding healthcare access.

What is the outlook for carvedilol phosphate in the next five years?
Moderate growth driven by geographic expansion and formulation innovation, offset by market saturation and generic competition.

---

Citations:

[1] World Health Organization. (2021). Cardiovascular diseases (CVDs). Retrieved from https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

[2] IMS Health. (2022). Global cardiovascular therapeutics market analysis. Internal report.

[3] Food and Drug Administration. (2007). FDA approval letter for Coreg CR.

[4] MarketWatch. (2023). Beta-blockers market size, share, and forecasts.